2023 was a landmark year for
These data, supported by validating partnerships, a strong cash position and solid investor base, set
Events in the fourth quarter
Positive data from clinical Phase 1/2a trial of BI-1808 as single agent were presented at SITC
Preclinical data providing clear evidence of the potential of anti-TNFR2 antibody BI-1910 were presented at SITC
Positive first clinical data on anti-FcyRIIB antibody BI-1607 presented at the San Antonio Breast Cancer Symposium
First patient enrolled in Phase 1/2a clinical trial with TNFR2 antibody BI-1910
Events after the end of the period
Supply agreement signed with
Earlier during 2023, in brief
A fourth complete response announced in Phase 1/2 trial with BI-1206 in non-Hodgkin's lymphoma
Management strengthened with the appointment of
Additional efficacy data announced from intravenous part of Phase 1/2 trial with BI-1206 in solid tumors
Strong interim safety data and early signs of efficacy reported in Phase 1/2a trial with anti-TNFR2 antibody BI-1808 in advanced malignancies
Research milestone event achieved in the collaboration with
= Regulatory event
Financial information
Fourth quarter 2023
Net sales
Profit/loss after tax
Profit/loss after tax per share before and after dilution
Cash flow from operating activities
January -
Net sales
Profit/loss after tax
Profit/loss after tax per share before and after dilution
Cash flow from operating activities
Liquid funds, current and long-term investments as of
INVITATION TO PRESENTATION OF YEAR-END REPORT 2023
When:
Listen to the presentation webcast: https://financialhearings.com/event/48630
To participate via teleconference, please register via the following link: https://conference.financialhearings.com/teleconference/id=50048630.
Upon registration, a phone number and conference ID for the conference call will be provided. You can ask questions verbally via the telephone conference.
About
The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company's fully integrated manufacturing unit.
Contact:
Tel: +46 (0)46 286 85 50
Email: cecilia.hofvander@bioinvent.com
Web: www.bioinvent.com
(C) 2024 Electronic News Publishing, source